Anti-BAFF-R
BAFF-R (B Cell Activating Factor Receptor) is a tumor necrosis factor (TNF) receptor superfamily member. As the main receptor for BAFF, BAFF-R expresses almost exclusively on B cells and is specifically involved in B lymphocyte differentiation and mature B-cell survival. The wide expression of BAFF-R on malignant B cells makes it a great potential tumor target. Dr. Larry Kwak’s laboratory discovered the novel humanized anti-BAFF-R monoclonal antibodies with high binding affinity and cytotoxic activities to various B cell tumor cells.
BAFFR CAR-T Cells
The BAFF-R CAR-T cell was developed using the anti-BAFF-R scFv (single-chain fragment variable) antibodies with the 2nd generation signaling domains containing CD3ζ and 4-1BB. Our researches have found that BAFF-R CAR-T cells kill lymphomas and leukemias in vitro and kill established lymphomas as well as leukemias in vivo. In 2017, PeproMene licensed this program from City of Hope National Medical Center.
BAFFR-BiTE
The BAFF-R BiTE was developed with anti-CD3 and anti-BAFF-R scFv antibodies using “knobs-into-holes” technology. PeproMene licensed this program from City of Hope in 2019. Our preliminary data of BAFF-R BiTE showed its in vitro antigen specific binding and cytotoxic activities, as well as in vivo eradication of established tumors. Further effort to optimize BAFF-R BiTE are currently ongoing.
BAFFR CAR-NK Cells
CAR-NK/ BAFFR CAR NK Cells
Natural killer cells (NK cells) are the first line of innate immune defense system to kill virus-infected and malignant cells. Because NK cells do not require HLA matching like T cell, it makes “off-the -shelf” NK cell therapy a viable option. Similar as CAR T cells, specific binding of CAR to its target antigen on tumor cells triggers the activation of CAR NK cells which will release of perforin and granzymes to kill tumor cells. Up to date, most CAR-T therapies consist of autologous T cells, whereas CAR-NK cell therapies can be generated from allogeneic donors.
PeproMene is currently assessing the possible partnership with companies having well-established innovative CAR-NK platform to co-develop allogeneic BAFFR CAR-NK therapy.
Similar as CAR T cells, specific binding of CAR to its target antigen on tumor cells triggers the activation of CAR NK cells which will release of perforin and granzymes to kill tumor cells. PeproMene is currently assessing the possible partnership with companies having well-established innovative CAR-NK platform to co-develop allogeneic BAFFR CAR-NK therapy.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Praesent orci velit, scelerisque id tincidunt non, porta non elit. Vestibulum ut massa a tellus interdum consectetur. Etiam molestie sodales massa, ac venenatis odio interdum imperdiet.
